...and up to about EUR20 million ($22.6 million) in milestones. Ipsen will gain SOMscan ( OPS202... ...SOMther ( OPS201 ), a radionuclide therapy labeled with yttrium-90 or lutetium-177 that antagonizes SSTR2. SOMscan...
...OctreoPharm said the European Commission granted Orphan Drug designation to OPS202 as a diagnostic agent for... ...gallium-68-labeled radioactive agent for PET imaging that antagonizes somatostatin receptor 2 (SSTR2) . OctreoPharm said OPS202... ...a European Phase I trial "soon." OctreoPharm Sciences GmbH , Berlin, Germany Product: SOMscan , OPS202...